| Title | Date | File Size | Download |
|---|---|---|---|
| Emergency Contraception Information Leaflet |
8 Apr, 2024 | 1,253.67 KB | Download |
| Hepatitis B Vaccination Patient Record Card |
8 Apr, 2024 | 47.91 KB | Download |
| HIV Post-exposure Prophylaxis (Information Leaflet) |
8 Apr, 2024 | 67.68 KB | Download |
| Referral letter to ID HIV Physician |
8 Apr, 2024 | 43.70 KB | Download |
| Significant Exposure to Bloodborne Viruses (Information Leaflet) |
8 Apr, 2024 | 432.51 KB | Download |
| Source Information Leaflet: Testing for hepatitis B, hepatitis C and HIV |
8 Apr, 2024 | 605.19 KB | Download |
| Checklist: Testing of source person or recipient for hepatitis B/hepatitis C/HIV |
8 Apr, 2024 | 68.09 KB | Download |
| Referral letter to GP or Occupational Health Department |
8 Apr, 2024 | 43.70 KB | Download |
| No Risk of Exposure Information Leaflet |
8 Apr, 2024 | 344.04 KB | Download |
| Striving to End Tuberculosis – A Strategy for Ireland 2024 - 2030 |
27 Mar, 2024 | 1,397.02 KB | Download |
| Evidence to decision: HIV PEP - Needlestick exposure from a discarded needle in the community and Shared injecting paraphernalia recommendations |
5 Mar, 2024 | 217.67 KB | Download |
| Evidence to decision: HIV PEP - Sexual exposure recommendations |
5 Mar, 2024 | 246.32 KB | Download |
| Evidence to decision: HIV PEP - Occupational exposure recommendations |
5 Mar, 2024 | 245.40 KB | Download |
| Evidence to decision: HIV PEP - Human bite exposure recommendations |
5 Mar, 2024 | 145.83 KB | Download |
| Summary of Recommendations: Guidelines for the Emergency Management of Injuries and Post-Exposure Prophylaxis (PEP) |
5 Mar, 2024 | 201.61 KB | Download |
| Table 11 - HIV PEP drugs, doses and side effects |
4 Mar, 2024 | 145.80 KB | Download |
| Table 10 - Suggested Paediatric PEP Regimens |
4 Mar, 2024 | 37.21 KB | Download |
| Table 9 - Estimated risk of HIV transmission by type of exposure where source HIV status is unknown |
4 Mar, 2024 | 123.04 KB | Download |
| Table 8 - Risk of HIV transmission per exposure where source is known to be living with HIV and not on ART |
4 Mar, 2024 | 68.26 KB | Download |
| Table 7 - Impact of suppressive antiretroviral therapy on risk of HIV acquisition |
4 Mar, 2024 | 92.17 KB | Download |
| Table 6 - HIV PEP recommendations by type of exposure and source status |
4 Mar, 2024 | 176.99 KB | Download |
| Table 5 - Baseline and follow up testing |
4 Mar, 2024 | 57.90 KB | Download |
| Table 4 - Hepatitis B post-exposure prophylaxis |
4 Mar, 2024 | 137.71 KB | Download |
| Table 3 - HIV Transmission risk by exposure type |
4 Mar, 2024 | 77.83 KB | Download |
| Table 2 - Hepatitis C transmission risk by exposure type |
4 Mar, 2024 | 118.71 KB | Download |
| Table 1 - Hepatitis B transmission risk by exposure type |
4 Mar, 2024 | 97.09 KB | Download |
| Management of Infection Risk from a Blood Borne Virus (BBV) following a needlestick or sharps injury in an Occupational or Community setting |
4 Mar, 2024 | 162.15 KB | Download |
| Management of Infection Risk following exposure of mucous membrane or non-intact skin to a Blood Borne Virus (BBV) in an occupational setting |
4 Mar, 2024 | 154.13 KB | Download |
| Management of Infection Risk from a Blood Borne Virus (BBV) following Sexual Exposure |
4 Mar, 2024 | 198.96 KB | Download |
| Management of Infection Risk from a Blood Borne Virus (BBV) following Human Bite breaching skin – or ‘fight bite’ |
4 Mar, 2024 | 160.29 KB | Download |
| Scabies Expert Advisory Group consensus on clinical, environmental, Infection Prevention and Control and contact tracing parameters for scabies |
26 Feb, 2024 | 271.33 KB | Download |
| Guidelines for the Emergency Management of Injuries (EMI) and Post-Exposure Prophylaxis (PEP) |
21 Feb, 2024 | 1,006.65 KB | Download |
| Template Letter to GP for close contacts of an iGAS case |
9 Feb, 2024 | 22.53 KB | Download |
| Summary of Recommendations: Guidelines for the Public Health Management of Contacts of Invasive Group A Streptococcus (iGAS) infection in Ireland. |
9 Feb, 2024 | 140.52 KB | Download |
| Template letter to GP for a case of iGAS |
9 Feb, 2024 | 20.13 KB | Download |
| Template letter for creche, school or other childcare setting |
9 Feb, 2024 | 19.60 KB | Download |
| Strep A (Group A streptococcus) factsheet |
9 Feb, 2024 | 177.18 KB | Download |
| Information leaflet for contacts of patients with Invasive Group A Streptococcal infection (iGAS) |
9 Feb, 2024 | 221.24 KB | Download |
| Template letter for GP – Close contact of iGAS case in an RCF setting |
9 Feb, 2024 | 708.22 KB | Download |
| Chapter 1: Introduction |
8 Feb, 2024 | 251.76 KB | Download |
| Appendix 1: SIGN-GRADE |
8 Feb, 2024 | 107.52 KB | Download |
| Table 5: Infection, Prevention and Control measures for RCFs This document is Table 5 from the Guidelines for the Public Health Management of Contacts of Invasive Group A Streptococcus (iGAS) Infection in Ireland. |
8 Feb, 2024 | 150.07 KB | Download |
| Framework for HSE National Programme for Surgical Site Surveillance – Pilot through the Irish Hip Fracture Database (IHFD). |
8 Feb, 2024 | 2,770.99 KB | Download |
| Choice of agent for treatment of Group A Streptococcus (GAS) or chemoprophylaxis for a contact of invasive Group A Streptococcus (iGAS) This document is Table 4 from the Guidelines for the Public Health Management of Contacts of Invasive Group A Streptococcus (iGAS) Infection in Ireland. |
8 Feb, 2024 | 112.20 KB | Download |
| Guidelines for the Public Health Management of Contacts of Invasive Group A Streptococcus (iGAS) infection in Ireland |
8 Feb, 2024 | 1,404.45 KB | Download |
| Chapter 5: Residential care facility (RCF) settings |
8 Feb, 2024 | 631.91 KB | Download |
| iGAS Guidelines References |
8 Feb, 2024 | 226.35 KB | Download |
| Chapter 6: Other congregate community settings |
8 Feb, 2024 | 200.17 KB | Download |
| Algorithm 6: Identification and Management of suspected or confirmed iGAS outbreak in a Residential Care Facility |
8 Feb, 2024 | 141.58 KB | Download |
| Chapter 3: Household settings |
8 Feb, 2024 | 224.53 KB | Download |
Ireland’s specialist service for the surveillance of communicable diseases.